Neurizon Therapeutics Valuation

Is NUZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NUZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NUZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NUZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUZ?

Key metric: As NUZ barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NUZ. This is calculated by dividing NUZ's market cap by their current book value.
What is NUZ's PB Ratio?
PB Ratio	9x
Book	AU$10.23m
Market Cap	AU$92.46m

NUZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	97.1x
Enterprise Value/EBITDA	-14.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does NUZ's PB Ratio compare to its peers?

The above table shows the PB ratio for NUZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	4.7x
SNT Syntara	13.5x	43.7%	AU$63.2m
IDT IDT Australia	1.8x	n/a	AU$43.0m
VLS Vita Life Sciences	2.4x	n/a	AU$117.1m
MVP Medical Developments International	1x	93.1%	AU$47.3m
NUZ Neurizon Therapeutics	9x	n/a	AU$92.5m

Price-To-Book vs Peers: NUZ is expensive based on its Price-To-Book Ratio (9x) compared to the peer average (4.7x).

Price to Book Ratio vs Industry

How does NUZ's PB Ratio compare vs other companies in the AU Pharmaceuticals Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
LGP Little Green Pharma	0.5x	110.1%	US$25.51m
EOF Ecofibre	0.4x	n/a	US$9.97m
CGB Cann Global	0.5x	n/a	US$3.69m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: NUZ is expensive based on its Price-To-Book Ratio (9x) compared to the Australian Pharmaceuticals industry average (4.4x).

Price to Book Ratio vs Fair Ratio

What is NUZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUZ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NUZ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

-5.6%

-46.8%

AVITA Medical

US$337.6m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

2.3%

20.4%

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

10.2%